HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展

Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophago⁃gastic adenocarcinoma

人表皮生长因子受体2(HER2)过表达或扩增胃及食管胃结合部腺癌可从抗HER2治疗中显著获益。目前,除曲妥珠单抗、帕妥珠单抗等人源化单克隆抗体外,多种针对HER2的抗体偶联药(恩美曲妥珠单抗、维迪西妥单抗、德喜曲妥珠单抗、ARX788)及酪氨酸激酶抑制剂(拉帕替尼、阿法替尼、吡咯替尼),可作为单一疗法或联合疗法应用于晚期胃及食管胃结合部腺癌的治疗,已在临床研究中显示出良好疗效,改善了患者预后及生命质量。进一步研究新型HER2靶向药物及联合治疗方案在临床治疗中的疗效与安全性,有望为HER2阳性晚期胃及食管胃结合部腺癌患者的治疗提供更有效的策略。

Patients with human epidermal growth factor receptor 2(HER2)overexpression or amplification in gastric and esophagogastic adenocarcinoma can significantly benefit from anti-HER2 therapies.Presently,various humanized monoclonal antibodies such as trastuzumab and pertuzumab,alongside diverse anti-HER2 antibody drug conjugates(trastuzumab emtansine,disitamab vedotin,trastuzumab deruxtecan,ARX788),and tyrosine kinase inhibitors(lapatinib,afatinib,pyrotinib),are employed either as monotherapy or in combination settings for advanced gastric and esophagogastic adenocarcinoma.These therapeutic modalities have demonstrated promising clinical efficacy in clinical trials,thereby ameliorating patients'prognosis and enhancing life quality.Further exploration on the efficacy and safety of novel HER2-targeted agents and combined therapeutic regimens in clinical practice holds the promise of furnishing more efficacious strategies for treating HER2-positive advanced gastric and esophagogastic adenocarcinoma.